SCHEMBL13720657

SCHEMBL13720657

C=C(O)c1ccc(NC(=S)N/N=C(\C)c2csc(-c3cccc(Cl)c3)c2O)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.43
HKDC1 Q2TB90 2/20 0.43
POLB P06746 1/20 0.39
CCR6 P51684 1/20 0.39
ATM Q13315 1/20 0.39
MAPT P10636 6/20 0.37
MEN1 O00255 5/20 0.37
KMT2A Q03164 5/20 0.37
ALOX12 P18054 2/20 0.37
NPC1 O15118 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
RRM1 P23921 1/20 0.34
RRM2 P31350 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12829661 0.91 HSP90AA1 (0.43) HSP90AA1HKDC1POLBCCR6ATM
SCHEMBL13934995 0.83 HSP90AA1 (0.46) HSP90AA1HKDC1POLBMAPTMEN1
SCHEMBL12830111 0.83 HSP90AA1 (0.46) HSP90AA1HKDC1POLBMAPTMEN1
SCHEMBL12829353 0.81 SIRT5 (0.46) HSP90AA1HKDC1POLBCCR6ATM
SCHEMBL1483366 0.81 SIRT5 (0.46) HSP90AA1HKDC1POLBCCR6ATM
SCHEMBL1483365 0.81 SIRT5 (0.46) HSP90AA1HKDC1POLBCCR6ATM
SCHEMBL12830126 0.81 MAPT (0.48) HSP90AA1HKDC1MAPTMEN1KMT2A
SCHEMBL12829347 0.80 SIRT5 (0.39) MAPTMEN1KMT2ALMNAALDH1A1
SCHEMBL1483112 0.80 SIRT5 (0.39) MAPTMEN1KMT2ALMNAALDH1A1
SCHEMBL1483111 0.80 SIRT5 (0.39) MAPTMEN1KMT2ALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576115-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-08-18 US disclosed
US-7576115-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-08-18 US disclosed
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2008-01-31 US disclosed
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2008-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 HSP90AA1 3712/4885HKDC1 3785/4885POLB 4323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.